Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Primary Endpoint Met for Revumenib in Patients with AML and ALL

Rekha Rao Manepalli, Ph.D, SMBA on LinkedIn: Revumenib Shows

I-131 apamistamab induces response among adults with advanced

Primary Endpoint Met for Revumenib in Patients with AML and ALL

Treatment - Cancer Currents Blog - NCI

MEN1 mutations mediate clinical resistance to menin inhibition

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

Transforming NCI Cancer Clinical Trials - NCI

Heather LaGrande on LinkedIn: Pembrolizumab for Advanced Triple

Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information